News

Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra
Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...
Fierce Pharma5d
Madrigal's Rezdiffra, the first-ever MASH drug, beats sales projections for 4 quarters in a row
Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...
Madrigal Pharmaceuticals advances Rezdiffra market penetration with 33% quarterly sales growth
Q1 2025 Management View CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite ...
BioPharma Dive6d
Madrigal’s MASH drug sales again top Wall Street projections
Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and ...
Zacks Investment Research on MSN6d
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Madrigal Pharmaceuticals MDGL reported first-quarter 2025 loss of $3.32 per share, narrower than the Zacks Consensus Estimate ...
Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...
Madrigal Pharmaceuticals Inc (MDGL) reports a 33% increase in net sales and significant patient growth, while navigating ...
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...
Seeking Alpha6d
Madrigal Pharmaceuticals advances Rezdiffra market penetration with 33% quarterly sales growth
CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite typical Q1 industry ...